Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015

- Presentation With Audio Webcast at 11:30 a.m. EDT -

BEDMINSTER, N.J., May 26, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY.

Jerome D. Jabbour, a Co-Founder and Chief Business Officer of Matinas BioPharma, will present a corporate overview on Thursday, May 28, 2015, at 11:30 a.m. EDT. As part of his presentation, Mr. Jabbour will discuss the clinical development strategy for MAT2203, a novel lipid-crystal nano-particle delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT2501, an early-stage program to treat gram-negative bacterial infections.

A live audio webcast of the presentation will be available on the Events page of the Investor Relations section of the Company's website (www.matinasbiopharma.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About the Fourth Annual SeeThru Equity Microcap Investor Conference

SeeThru Equity is the premier and unbiased provider of microcap equity research and institutional and high net worth investor focused conferences. Since its inception in 2011, the firm has grown to over 125 companies under coverage and has successfully hosted 14 investor conferences. The Fourth Annual Microcap Investor Conference brings together over 60 presenting companies and 600 attendees. The conference offers detailed presentations, targeted one-on-one meetings and numerous networking opportunities.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel lipid-based pharmaceutical products for the treatment of infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. Recent additions to its product pipeline, including MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the expected use of proceeds from the offering, the Company's cash flow and working capital needs and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

CONTACT: Investor and Media Contact
         Jenene Thomas
         Investor Relations and Corporate Communications Advisor
         Jenene Thomas Communications, LLC
         Phone: +1 (908) 938-1475
         Email: jthomas@matinasbiopharma.com

Released May 26, 2015